This Israeli startup has developed the world’s first miniature implant for left-atrial monitoring, following repair of a complex congenital heart failure
Israeli medical technology startup, Vectorious Medical Technologies, has developed the world’s first miniature implant for left-atrial monitoring. The monitoring is necessary following repair of a complex congenital heart failure. Using Closed-loop CHF Therapy, the technology helps physicians to help patients help themselves. Via a simple, minimally-invasive implanted device, easy-to-access data and user-friendly external home-unit; the VectoriousTM system increases CHF patient quality of life and reduces readmission rates. With daily ‘push button’ readings of patient hemodynamic pressure provide early, accurate physiological indication of cardiac decompensation. The medical device is currently not available for sale within the United States or internationally.
The company also announced it has raised $9.5 million in a Series B funding round led by Boston-based Broadview Ventures and China’s GEOC, with the participation of Israel-based investors. Back in 2015, the company raised $5 million in venture round from three investors, including Cleveland Clinic. The company also received a grant from the Israel Innovation Authority and a $2.2 million grant from Horizon 2020 and the flagship R&D program of the EU.
“This additional financing round is a vote of confidence in Vectorius’s solution and has major significance when it comes from the world’s leading venture capital funds and medical centers and the EU. Chronic lack of supply to the heart is one of the most common causes of death in the western world. 1.2 million people are hospitalized each year in the US from deterioration of the disease at a cost of $32 billion to the US health system. In addition, half of patients need to be re-hospitalized after six months because of defective diagnosis and treatment. Vectorius’s product will prevent the disease from worsening, improve the quality of life of the patient and lengthen their lives.”
Founded in 2011 byOren Goldshtein (CEO), Dr. Eyal Orion, and Roni Weinstein, Vectorious Medical Technologies enables closed-loop therapy for congestive heart failure. The company has developed a novel approach to implantable long term hemodynamic monitoring that leverages state-of-the-art technologies in two areas: direct measurement of left atrial pressure and wireless communications. The device comes with optimal physiological indication tracking, an innovative, miniature, wireless sensory implant that enables the hemodynamic monitoring of left atrial pressure for accurate, daily physiological indication and optimized CHF patient management. According to its website, the device is safe and comes with a miniature sensory implant delivered via a minimally invasive procedure enables low risk delivery and reduced long-term complications.